Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:

  • why certain trials have failed whereas others have succeeded,
  • what we have learned about the connection between overall survival and progression-free survival as endpoints, and
  • how the systemic therapy of HCC has evolved.


  • Prof. Peter Galle (Moderator)
  • Prof. Bruno Sangro (Faculty)
  • Dr Anna Saborowski (Faculty)
  • Prof. Arndt Vogel (Faculty)

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.


Log in to post comments